Trials / Completed
CompletedNCT00109278
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,100 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).
Detailed description
The duration of treatment is 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V205C, measles, mumps, and rubella virus vaccine live | |
| BIOLOGICAL | Comparator: Measles, Mumps, and Rubella Virus Vaccine Live |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2005-05-01
- Completion
- 2005-05-01
- First posted
- 2005-04-26
- Last updated
- 2017-03-15
Source: ClinicalTrials.gov record NCT00109278. Inclusion in this directory is not an endorsement.